Antimicrobial activity of ceftolozane/tazobactam tested against Gram-negative bacterial isolates from hospitalised patients with pneumonia in European hospitals (2011) (oral)
Antimicrobial activity of ceftolozane/tazobactam tested against Gram-negative bacterial isolates from hospitalised patients with pneumonia in European hospitals (2011) (oral), Lead author: Sader HS, presented at 23rd annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 27 – 30, 2013, Berlin, Germany
Molecular characterisation of Staphylococcus aureus isolates that are non-susceptible to ceftaroline isolated during the 2010 surveillance programme (oral)
Molecular characterisation of Staphylococcus aureus isolates that are non-susceptible to ceftaroline isolated during the 2010 surveillance programme (oral), Lead author: Alm, presented at 23rd annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 27 – 30, 2013, Berlin, Germany
Is what you see what you get? Product variation in clinical and reference formulations of polymyxin B
Is what you see what you get? Product variation in clinical and reference formulations of polymyxin B, Lead author: Kassamali, presented at 23rd annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 27 – 30, 2013, Berlin, Germany
Characterisation of three new VIM enzymes, VIM-35, VIM-36 and VIM-37 identified in European countries: report of the SENTRY Antimicrobial Surveillance Programme
Characterisation of three new VIM enzymes, VIM-35, VIM-36 and VIM-37 identified in European countries: report of the SENTRY Antimicrobial Surveillance Programme, Lead author: Castanheira M, presented at 23rd annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 27 – 30, 2013, Berlin, Germany
Beta-lactamase production among ceftazidime-resistant Pseudomonas aeruginosa from five European countries: high prevalence of oxacillinases and VIM enzymes in the SENTRY Programme
Beta-lactamase production among ceftazidime-resistant Pseudomonas aeruginosa from five European countries: high prevalence of oxacillinases and VIM enzymes in the SENTRY Programme, Lead author: Castanheira M, presented at 23rd annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 27 – 30, 2013, Berlin, Germany
AmpC and MexAB-OprM hyperexpression are most common mechanisms among ceftazidime- and imipenem-resistant Pseudomonas aeruginosa from Chinese hospitals
AmpC and MexAB-OprM hyperexpression are most common mechanisms among ceftazidime- and imipenem-resistant Pseudomonas aeruginosa from Chinese hospitals, Lead author: Castanheira M, presented at 23rd annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 27 – 30, 2013, Berlin, Germany
Detection of plasmid-encoded CFR in clinical isolates of Enterococcus faecalis from Panamá City: report from the SENTRY Antimicrobial Surveillance Programme
Detection of plasmid-encoded CFR in clinical isolates of Enterococcus faecalis from Panamá City: report from the SENTRY Antimicrobial Surveillance Programme, Lead author: Mendes RE, presented at 23rd annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 27 – 30, 2013, Berlin, Germany
Susceptibility rates in Latin American nations: report from the Emerging Markets Resistance Surveillance Programme
Susceptibility rates in Latin American nations: report from the Emerging Markets Resistance Surveillance Programme, Lead author: Jones RN, presented at 23rd annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 27 – 30, 2013, Berlin, Germany
Resistance surveillance programme report for European nations (2011)
Resistance surveillance programme report for European nations (2011), Lead author: Jones RN, presented at 23rd annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 27 – 30, 2013, Berlin, Germany
Longitudinal assessment of tigecycline activity tested against Gram-positive and Gram-negative organisms from European medical centres: results from the SENTRY Programme (2004-2012)
Longitudinal assessment of tigecycline activity tested against Gram-positive and Gram-negative organisms from European medical centres: results from the SENTRY Programme (2004-2012), Lead author: Sader HS, presented at 23rd annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 27 – 30, 2013, Berlin, Germany
Antimicrobial susceptibility of Gram-negative bacteria causing urinary tract infections in European and United States hospitals (2009-2011)
Antimicrobial susceptibility of Gram-negative bacteria causing urinary tract infections in European and United States hospitals (2009-2011), Lead author: Sader HS, presented at 23rd annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 27 – 30, 2013, Berlin, Germany
Screening for fluoroquinolone-resistance in staphylococcus aureus and Streptococcus spp using norfloxacin and EUCAST disc diffusion criteria
Screening for fluoroquinolone-resistance in staphylococcus aureus and Streptococcus spp using norfloxacin and EUCAST disc diffusion criteria, Lead author: Ahman, presented at 23rd annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 27 – 30, 2013, Berlin, Germany
Improved screen for beta-lactam-resistance in Streptococcus pneumoniae with the oxacillin 1-ug disk using the EUCAST disc diffusion method
Improved screen for beta-lactam-resistance in Streptococcus pneumoniae with the oxacillin 1-ug disk using the EUCAST disc diffusion method, Lead author: Matuschek, presented at 23rd annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 27 – 30, 2013, Berlin, Germany
Biapenem and biapenem/RPX7009 MIC quality control ranges using CLSI multi-laboratory M23-A3 study design
Biapenem and biapenem/RPX7009 MIC quality control ranges using CLSI multi-laboratory M23-A3 study design, Lead author: Flamm R, presented at 23rd annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 27 – 30, 2013, Berlin, Germany
Activity of aztreonam combined with the beta-lactamase inhibitor avibactam tested against metallo beta-lactamase-producing organisms
Activity of aztreonam combined with the beta-lactamase inhibitor avibactam tested against metallo beta-lactamase-producing organisms, Lead author: Castanheira M, presented at 23rd annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 27 – 30, 2013, Berlin, Germany
Antimicrobial activity of ceftaroline and comparator agents tested against organisms causing skin and soft tissue infections in European medical centres (2011)
Antimicrobial activity of ceftaroline and comparator agents tested against organisms causing skin and soft tissue infections in European medical centres (2011), Lead author: Sader HS, presented at 23rd annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 27 – 30, 2013, Berlin, Germany
Antimicrobial activity of ceftaroline combined with avibactam tested against contemporary (2012) bacteria collected from USA patients with acute bacterial skin and skin structure infections
Antimicrobial activity of ceftaroline combined with avibactam tested against contemporary (2012) bacteria collected from USA patients with acute bacterial skin and skin structure infections, Lead author: Sader HS, presented at 23rd annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 27 – 30, 2013, Berlin, Germany
Ceftaroline activity tested against uncommonly isolated Gram-positive pathogens (2008-2011)
Ceftaroline activity tested against uncommonly isolated Gram-positive pathogens (2008-2011), Lead author: Sader HS, presented at 23rd annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 27 – 30, 2013, Berlin, Germany
Activity of ceftaroline against the leading community-acquired respiratory tract infection pathogens in Europe and the Mediterranean region, 2011
Activity of ceftaroline against the leading community-acquired respiratory tract infection pathogens in Europe and the Mediterranean region, 2011, Lead author: Flamm R, presented at 23rd annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 27 – 30, 2013, Berlin, Germany
Activity of ceftobiprole tested against pathogens associated with hospital-acquired bacterial pneumonia in Europe
Activity of ceftobiprole tested against pathogens associated with hospital-acquired bacterial pneumonia in Europe, Lead author: Flamm R, presented at 23rd annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 27 – 30, 2013, Berlin, Germany
Activity of ceftobiprole tested against pathogens associated with community-acquired bacterial pneumonia in Europe
Activity of ceftobiprole tested against pathogens associated with community-acquired bacterial pneumonia in Europe, Lead author: Flamm R, presented at 23rd annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 27 – 30, 2013, Berlin, Germany
Activity of ceftobiprole tested against Gram-negative clinical isolates from European medical centres
Activity of ceftobiprole tested against Gram-negative clinical isolates from European medical centres, Lead author: Flamm R, presented at 23rd annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 27 – 30, 2013, Berlin, Germany
Activity of ceftobiprole tested against clinical isolates of staphylococci and streptococci from European surveillance (2008-2010)
Activity of ceftobiprole tested against clinical isolates of staphylococci and streptococci from European surveillance (2008-2010), Lead author: Flamm R, presented at 23rd annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 27 – 30, 2013, Berlin, Germany
Activity of ceftobiprole against methicillin-resistant Staphylococcus aureus including strains with reduced susceptibility to daptomycin, linezolid, and vancomycin
Activity of ceftobiprole against methicillin-resistant Staphylococcus aureus including strains with reduced susceptibility to daptomycin, linezolid, and vancomycin, Lead author: Flamm R, presented at 23rd annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 27 – 30, 2013, Berlin, Germany
Antimicrobial activity of ceftolozane/tazobactam and comparator agents tested against Pseudomonas aeruginosa isolates from 14 European countries and Israel
Antimicrobial activity of ceftolozane/tazobactam and comparator agents tested against Pseudomonas aeruginosa isolates from 14 European countries and Israel, Lead author: Sader HS, presented at 23rd annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 27 – 30, 2013, Berlin, Germany
Oritavancin activity tested against Staphylococcus aureus and beta-haemolytic streptococci causing skin and soft tissue infections in the European Union and other countries (2010-2012)
Oritavancin activity tested against Staphylococcus aureus and beta-haemolytic streptococci causing skin and soft tissue infections in the European Union and other countries (2010-2012), Lead author: Mendes RE, presented at 23rd annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 27 – 30, 2013, Berlin, Germany
Assessment of oritavancin activity tested against contemporary clinical isolates responsible for documented bacteremia in the European Union and other countries (2010-2012)
Assessment of oritavancin activity tested against contemporary clinical isolates responsible for documented bacteremia in the European Union and other countries (2010-2012), Lead author: Mendes RE, presented at 23rd annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 27 – 30, 2013, Berlin, Germany
Dalbavancin activity in the USA: reported from the SENTRY Programme (2012)
Dalbavancin activity in the USA: reported from the SENTRY Programme (2012), Lead author: Jones RN, presented at 23rd annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 27 – 30, 2013, Berlin, Germany
Pharmacokinetics-pharmacodynamics of tazobactam in combination with ceftolozane in an in vitro infection model
Pharmacokinetics-pharmacodynamics of tazobactam in combination with ceftolozane in an in vitro infection model, Lead author: Bhavnani, presented at 23rd annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 27 – 30, 2013, Berlin, Germany
Recent Resistance Surveillance Results from 12 Medical Centres Across China (2011)
Recent Resistance Surveillance Results from 12 Medical Centres Across China (2011), Lead author: Mendes RE, presented at 9th annual International Symposium on Antimicrobial Agents and Resistance (ISAAR), March 12 – 15, 2013, Kuala Lumpur, Malaysia
Molecular Characterization of Vancomycin-resistant Enterococcus Clinical Isolates Recovered from Hospitalized Patients in China
Molecular Characterization of Vancomycin-resistant Enterococcus Clinical Isolates Recovered from Hospitalized Patients in China, Lead author: Mendes RE, presented at 9th annual International Symposium on Antimicrobial Agents and Resistance (ISAAR), March 12 – 15, 2013, Kuala Lumpur, Malaysia
Emerging Markets Resistance Surveillance Programme Report for 12 Asia-Pacific Nations (2011)
Emerging Markets Resistance Surveillance Programme Report for 12 Asia-Pacific Nations (2011), Lead author: Mendes RE, presented at 9th annual International Symposium on Antimicrobial Agents and Resistance (ISAAR), March 12 – 15, 2013, Kuala Lumpur, Malaysia
Telavancin In Vitro Activity Against a Contemporary(2011–2012) Collection of Gram-positive Pathogens
Telavancin In Vitro Activity Against a Contemporary(2011–2012) Collection of Gram-positive Pathogens, Lead author: Mendes RE, presented at 9th annual International Symposium on Antimicrobial Agents and Resistance (ISAAR), March 12 – 15, 2013, Kuala Lumpur, Malaysia
Antimicrobial activity of ceftaroline tested against staphylococci with reduced susceptibility to linezolid, daptomycin or vancomycin from USA hospitals (2008–2011).
Antimicrobial activity of ceftaroline tested against staphylococci with reduced susceptibility to linezolid, daptomycin or vancomycin from USA hospitals (2008–2011). by Sader HS, Flamm RK and Jones RN published in Antimicrob. Agents Chemother. 2013; 57 (7): 3178-3181
Linezolid surveillance results for the United States: LEADER Surveillance Program 2011.
Linezolid surveillance results for the United States: LEADER Surveillance Program 2011. by Flamm RK, Mendes RE, Ross JE, Sader HS and Jones RN published in Antimicrob. Agents Chemother. 2013; 57 (2): 1077-1081
Antimicrobial activity of daptomycin tested against Gram-positive pathogens collected in Europe, Latin America, and selected countries in the Asia-Pacific Region (2011).
Antimicrobial activity of daptomycin tested against Gram-positive pathogens collected in Europe, Latin America, and selected countries in the Asia-Pacific Region (2011). by Sader HS, Flamm RK and Jones RN published in Diagn. Microbiol. Infect. Dis. 2013; 75 (4): 417-422
Educational antimicrobial susceptibility testing as a critical component of microbiology laboratory proficiency programs: American Proficiency Institute (API) results for 2007-2011.
Educational antimicrobial susceptibility testing as a critical component of microbiology laboratory proficiency programs: American Proficiency Institute (API) results for 2007-2011. by Jones RN, Glick T, Sader HS, Flamm RK, Ross JE, Rhomberg PR and Edson DC published in Diagn. Microbiol. Infect. Dis. 2013; 75 (4): 357-360
Update on antimicrobial susceptibility trends among Streptococcus pneumoniae in the United States: Report of ceftaroline activity from the SENTRY Antimicrobial Surveillance Program (1998-2011).
Update on antimicrobial susceptibility trends among Streptococcus pneumoniae in the United States: Report of ceftaroline activity from the SENTRY Antimicrobial Surveillance Program (1998-2011). by Jones RN, Sader HS, Mendes RE and Flamm RK published in Diagn. Microbiol. Infect. Dis. 2013; 75 (1): 107-109
Antimicrobial activity of the novel polymyxin derivative NAB739 tested against Gram-negative pathogens.
Antimicrobial activity of the novel polymyxin derivative NAB739 tested against Gram-negative pathogens. by Vaara M, Sader HS, Rhomberg PR, Jones RN and Vaara T published in J. Antimicrob. Chemother. 2013; 68 (3): 636-639
Candida guilliermondii and other species of Candida misidentified as Candida famata: Assessment by Vitek2, ITS sequence analysis and Matrix-Assisted Laser Desorption Ionization–Time of Flight Mass Spectrometry in two global surveillance programs.
Candida guilliermondii and other species of Candida misidentified as Candida famata: Assessment by Vitek2, ITS sequence analysis and Matrix-Assisted Laser Desorption Ionization–Time of Flight Mass Spectrometry in two global surveillance programs. by Castanheira M, Woosley LN, Diekema DJ, Jones RN and Pfaller MA published in J. Clin. Microbiol. 2013; 51 (1): 117-124
Update on the prevalence and genetic characterization of NDM-1-producing Enterobacteriaceae in Indian hospitals during 2010.
Update on the prevalence and genetic characterization of NDM-1-producing Enterobacteriaceae in Indian hospitals during 2010. by Castanheira M, Deshpande LM, Farrell SE, Shetye S, Shah N and Jones RN published in Diagn. Microbiol. Infect. Dis. 2013; 75 (2): 210-213
Activity of MK-3118, a new oral glucan synthase inhibitor tested against Candida spp. by two international methods (CLSI and EUCAST).
Activity of MK-3118, a new oral glucan synthase inhibitor tested against Candida spp. by two international methods (CLSI and EUCAST). by Pfaller MA, Messer SA, Motyl MR, Jones RN and Castanheira M published in J. Antimicrob. Chemother. 2013; 68 (4): 858-863
In vitro activity of a new oral glucan synthase inhibitor (MK-3118) tested against Aspergillus spp. by CLSI and EUCAST broth microdilution methods.
In vitro activity of a new oral glucan synthase inhibitor (MK-3118) tested against Aspergillus spp. by CLSI and EUCAST broth microdilution methods. by Pfaller MA, Messer SA, Motyl MR, Jones RN and Castanheira M published in Antimicrob. Agents Chemother. 2013; 57 (2): 1065-1068
Determination of disk diffusion and MIC quality control guidelines for GSK2251052: A novel boron antibacterial.
Determination of disk diffusion and MIC quality control guidelines for GSK2251052: A novel boron antibacterial. by Ross JE, Scangarella-Oman NE and Jones RN published in Diagn. Microbiol. Infect. Dis. 2013; 75 (4): 437-439
Update of dalbavancin spectrum and potency in the USA; Report from the SENTRY Antimicrobial Surveillance Program (2011).
Update of dalbavancin spectrum and potency in the USA; Report from the SENTRY Antimicrobial Surveillance Program (2011). by Jones RN, Sader HS and Flamm RK published in Diagn. Microbiol. Infect. Dis. 2013; 75 (3): 304-307
Surveillance of dalbavancin potency and spectrum in the United States (2012).
Surveillance of dalbavancin potency and spectrum in the United States (2012). by Jones RN, Flamm RK and Sader HS published in Diagn. Microbiol. Infect. Dis. 2013; 76 (1): 122-123
Interim susceptibility testing for ceftaroline, a new MRSA-active cephalosporin: Selecting potent surrogate ß-lactam markers to predict ceftaroline activity against clinically-indicated species.
Interim susceptibility testing for ceftaroline, a new MRSA-active cephalosporin: Selecting potent surrogate ß-lactam markers to predict ceftaroline activity against clinically-indicated species. by Jones RN, Flamm RK, Sader HS and Stilwell MG published in Diagn. Microbiol. Infect. Dis. 2013; 75 (1): 89-93
Antimicrobial activity of ceftaroline-avibactam tested against recent clinical isolates from USA medical centers (2010-2011).
Antimicrobial activity of ceftaroline-avibactam tested against recent clinical isolates from USA medical centers (2010-2011). by Sader HS, Flamm RK and Jones RN published in Antimicrob. Agents Chemother. 2013; 57 (4): 1982-1988
Antimicrobial activity of ceftaroline and comparator agents tested against bacterial isolates causing skin and soft tissue infections and community-acquired respiratory tract infections isolated from the Asia-Pacific region and South Africa (2010).
Antimicrobial activity of ceftaroline and comparator agents tested against bacterial isolates causing skin and soft tissue infections and community-acquired respiratory tract infections isolated from the Asia-Pacific region and South Africa (2010). by Sader HS, Flamm RK and Jones RN published in Diagn. Microbiol. Infect. Dis. 2013; 76 (1): 61-68
Spectrum and potency of ceftaroline tested against leading pathogens causing community-acquired respiratory tract infections in Europe (2010).
Spectrum and potency of ceftaroline tested against leading pathogens causing community-acquired respiratory tract infections in Europe (2010). by Farrell DJ, Flamm RK, Jones RN and Sader HS published in Diagn. Microbiol. Infect. Dis. 2013; 75 (1): 86-88
